Revolutionizing healthcare conversational data with Drug-GPT and Socialgist

In a digital era where countless conversations unfold online every minute, deciphering the intricate network of dialogues within the healthcare domain has become essential, especially for Healthcare Marketing Strategists. Our exploration this week highlights how Drug-GPT’s synergy with Socialgist is set to revolutionize Strategists’ approach to harnessing Healthcare Conversational Data. This blog takes a look at how Advanced Data Science and Artificial Intelligence through Drug-GPT can be used to curate and analyze the vast array of publicly available social conversations. 

The Challenge of Scale 

Online conversations, spanning various platforms and languages, create a complex network of global communication that is both beneficial and overwhelming. The sheer volume of data can be daunting: millions of tweets, blog posts, reviews, and comments generated daily. Reddit, for example, has logged 550 million conversations for 2024 with the growth projection forecasting 682 million conversations by 2026.  Each piece of data offers insights into public opinion, emerging trends, and Patient behavior. However, efficiently extracting accurate information from these large datasets can be challenging. Together, Socialgist and Drug-GPT streamline this process. 

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams. The Talking Medicines mission is to be the World’s Gold Standard for Patient Intelligence by Medicine.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
Tern plc

More articles like this

Tern plc

Cybersecurity complexities in the medical device industry

Paul Lockley – VP Sales, EMEA: Recently, I had the pleasure of speaking at the 6th Annual European Medical Device and Diagnostic Cybersecurity Conference. The event covered a wide range of cyber-related issues, including SBOM complexities, the

Tern plc

The opportunities of AI in healthcare

Talking Medicines co-founder Scott Crae was invited by the Ethical Medicines Industry Group (EMIG) to present on the opportunities for AI tools in a data-driven healthcare environment. EMIG is a multi-stakeholder network and trade association representing

Tern plc

Why Privileged Access Management is essential for cybersecurity

Privileged Access Management (PAM) is fundamental to cybersecurity strategies, monitoring and protecting privileged accounts that have the authority to make significant changes within IT environments. It plays a crucial role in safeguarding against internal and external

Tern plc

Unlocking the potential of IoT through satellite connectivity

The Internet of Things (IoT) excites many due to its potential to surface critical information swiftly, bypassing the delays of human intervention. By leveraging real-time data, businesses can achieve efficiencies, support innovative business models, and derive

Tern plc

Medical training with AI and VR

The convergence of Immersive Virtual Reality (VR) and Artificial Intelligence (AI) is transforming medical training, offering personalised learning experiences, enhancing engagement, and empowering educators with real-time insights. Despite the challenges and considerations, the benefits of AI

Tern plc

Securing networks with IAM Zero Trust

In today’s security landscape, the assumption of trust is no longer viable, necessitating a stringent approach to network protection. IAM Zero Trust embodies this by enforcing the principle of ‘never trust, always verify.’ This model requires

Tern plc

Growing the Internet of Things to ensure success

The Internet of Things (IoT) is expanding rapidly, with an ever-increasing number of devices and use cases marking the advent of a new era in connectivity. Advances in artificial intelligence are significantly contributing to this growth.

FundamentalVR announces groundbreaking AI integration in surgical training

FundamentalVR, a global leader in immersive surgical training, has made significant advancements in its Fundamental Surgery platform by integrating cutting-edge artificial intelligence (AI) capabilities. These enhancements aim to drive predictive insights, improve surgical proficiency, and accelerate

Tern plc

Developing and maintaining Identity and Access Management policies

Safeguarding your business’s digital assets while providing appropriate access levels is crucial. Identity and Access Management (IAM) policies play a vital role in organisational security, ensuring that only authorised individuals have access to critical systems and

Tern plc

AI is revolutionising healthcare strategies

In the dynamic landscape of healthcare, the continuous evolution of drug development and patient engagement necessitates ongoing innovation. Recently, GLP-1 drugs have garnered considerable attention for their revolutionary impact on treating various medical conditions, including weight

Tern plc

Understanding Identity Access Management solutions

Identity Access Management (IAM) solutions play a critical role in minimising cyber and data governance risks by tracking and restricting access to digital systems. Fundamentally, IAM solutions capture and log user login information, manage the database

Tern plc

Device Authority welcomes new VP of Customer Success

Device Authority, a recognised global leader in Identity and Access Management (IAM) for Enterprise IoT ecosystems, has announced the addition of Steve Huehmer, an experienced Customer Success expert, to their team. Steve Huehmer, based in Boston,

Revolutionising global IoT connectivity

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams. Wyld Networks is uniquely placed to deliver fixed and mobile mesh technology

Tern plc

Tern’s FY23 results show promising metrics and strategic growth

Tern’s FY23 results showcase improving metrics that are likely to attract additional strategic interest across its portfolio. All companies within Tern’s portfolio are experiencing significant commercial traction. Configuration work is transitioning to repeat licencing through SaaS

Tern plc

Pioneering solutions for obesity and type 2 diabetes

As the quest for the ultimate solution to type 2 diabetes heats up, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) agonists have emerged as game-changing treatments, revolutionising the management of type 2 diabetes and obesity.